#LCSM Chat Topic 6/29: When Doctors Disagree
Increasingly, the care of lung cancer patients has become a multi-doctor, multi-disciplinary job. Gone are the days (thankfully!) when a paternalistic doctor prescribed a treatment plan that was unquestioned by the patient. The internet and ease of travel have allowed unprecedented access to information and to physicians. As more treatment options and strategies become available for lung cancer patients, it is inevitable that they will be faced with differing opinions from their physicians with regard to how to personalize their care. Examples are plentiful, such as decisions between surgery or radiation therapy… Read More
#LCSM Chat Topic 5/18: What’s PFS Got to Do with It?
For our chat on 5/18/17, starting at 8 PM Eastern, 5 PM Pacific, we’ll cover several key trial results and the potential implications of them. While each has the potential to be practice changing, all three have the primary endpoint of progression-free survival (PFS) but, to our knowledge, don’t necessarily improve overall survival (OS). It is interesting that the differences between the settings and trial designs have led many lung cancer experts to favor adoption of some of these results but not necessarily others. But what do patients and caregivers think of… Read More
#LCSM Chat Topic 4/6: Who Needs Research Anyway: How Have You Been Impacted by Lung Cancer Research?
Our topic for the next #LCSM Chat on Thursday, April 6th at 5 PM Pacific/ 8 PM Eastern is “Who Needs Research Anyway: How Have You Been Impacted by Lung Cancer Research?” The moderator for this chat is Dr. David Tom Cooke (@DavidCookeMD) In its most recent budget outline, the Trump administration is looking to propose an 18% cut to the National Institute of Health’s (NIH; @NIH) $31.7 billion budget (#trumpbudget). In addition to this funding cut, the Trump administration proposes to 1) reorganize the current NIH institute structure and 2)… Read More
#LCSM 
You must be logged in to post a comment.